title: Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients.
abstract: OBJECTIVE
  Recent studies have been made of the novel treatment of lower limb spasticity after stroke with botulinum toxin A, and the results were based mostly on the clinical assessment made before and after treatment. This study investigated the effects of toxin on ankle muscle activity during gait in patients with severe extensor spasticity. The questions posed were whether the toxin particularly diminishes the so-called premature muscle activity as a major cause of equinovarus deformity and whether different types of altered motor control allow a prediction of the outcome of the treatment.
  
  
  METHODS
  In 12 chronic hemiparetic outpatients with pronounced lower limb spasticity, we injected 400 U botulinum toxin A into the soleus and tibialis posterior muscles and both heads of the gastrocnemius muscles. Ankle spasticity and complex gait analysis including kinematic electromyography (EMG) of the soleus and tibialis muscles were assessed before treatment and 4 weeks after the injection.
  
  
  RESULTS
  Nine patients profited with a reduction of spasticity, improved gait ability, and a more normal temporal pattern of muscle activity with a prominent reduction of the premature activity of the plantar flexors. Eight patients exhibited a qualitative pattern (type I) corresponding to an increased stretch-reflex excitability. Three patients did not profit; their muscle tone, gait ability, and muscle activation remained stable or even deteriorated.
  
  
  CONCLUSIONS
  This study further supports the beneficial effects of botulinum toxin in the treatment of lower limb extensor spasticity. A correlation was observed between the clinical reduction of muscle tone, functional gait parameters, and a more normal EMG pattern with a predominant reduction of the premature activity of the plantar flexors. The qualitative type of EMG pattern corresponding to an increased stretch-reflex excitability (type I) was a positive predictor for the outcome.
authors.affiliation: Klinik Berlin, Department of Neurological Rehabilitation, Free University Berlin (Germany).
authors.forename: S
authors.initials: S
authors.lastname: Hesse
authors.forename: J
authors.initials: J
authors.lastname: Krajnik
authors.forename: D
authors.initials: D
authors.lastname: Luecke
authors.forename: M T
authors.initials: MT
authors.lastname: Jahnke
authors.forename: M
authors.initials: M
authors.lastname: Gregoric
authors.forename: K H
authors.initials: KH
authors.lastname: Mauritz
mesh_terms: D000328:Adult; D000368:Aged; D000842:Ankle; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000150:complications; D002908:Chronic Disease; D004576:Electromyography; D004863:Equinus Deformity / Q000209:etiology; D005260:Female; D005544:Forecasting; D005684:Gait; D006429:Hemiplegia / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction; D009128:Muscle Spasticity / Q000503:physiopathology / Q000628:therapy*; D009129:Muscle Tonus; D018482:Muscle, Skeletal / Q000503:physiopathology*; D012026:Reflex, Stretch; D016896:Treatment Outcome
chemical_list: D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins